Local immunotherapy
1998; Wiley; Volume: 53; Issue: 10 Linguagem: Inglês
10.1111/j.1398-9995.1998.tb03793.x
ISSN1398-9995
AutoresH.‐J. Malling, J. Abreu‐Nogueira, Emilio Alvarez‐Cuesta, Bengt Björkstén, Jean Bousquet, D. Caillot, Giorgio Walter Canonica, Giovanni Passalacqua, P. Saxonis‐Papageorgiou, Erkka Valovirta,
Tópico(s)Asthma and respiratory diseases
ResumoAllergyVolume 53, Issue 10 p. 933-943 Local immunotherapy H.-J. Malling, Corresponding Author H.-J. Malling Members of the EAACI Immunotherapy SubcommitteeHans-Jørgen Mailing, MD Allergy Unit 7551 National University Hospital Tagensvej 20 DK-2200 Copenhagen N DenmarkSearch for more papers by this authorJ. Abreu-Nogueira, J. Abreu-Nogueira Members of the ESPACI Immunotherapy CommitteeSearch for more papers by this authorE. Alvarez-Cuesta, E. Alvarez-Cuesta Members of the EAACI Immunotherapy Subcommittee Members of the ESPACI Immunotherapy CommitteeSearch for more papers by this authorB. Björkstén, B. Björkstén Members of the ESPACI Immunotherapy CommitteeSearch for more papers by this authorJ. Bousquet, J. Bousquet Members of the EAACI Immunotherapy SubcommitteeSearch for more papers by this authorD. Caillot, D. Caillot Members of the EAACI Immunotherapy Subcommittee Members of the ESPACI Immunotherapy CommitteeSearch for more papers by this authorG. W. Canonica, G. W. Canonica Members of the EAACI Immunotherapy SubcommitteeSearch for more papers by this authorG. Passalacqua, G. Passalacqua Members of the EAACI Immunotherapy SubcommitteeSearch for more papers by this authorP. Saxonis-Papageorgiou, P. Saxonis-Papageorgiou Members of the EAACI Immunotherapy SubcommitteeSearch for more papers by this authorE. Valovirta, E. Valovirta Members of the EAACI Immunotherapy Subcommittee Members of the ESPACI Immunotherapy CommitteeSearch for more papers by this author H.-J. Malling, Corresponding Author H.-J. Malling Members of the EAACI Immunotherapy SubcommitteeHans-Jørgen Mailing, MD Allergy Unit 7551 National University Hospital Tagensvej 20 DK-2200 Copenhagen N DenmarkSearch for more papers by this authorJ. Abreu-Nogueira, J. Abreu-Nogueira Members of the ESPACI Immunotherapy CommitteeSearch for more papers by this authorE. Alvarez-Cuesta, E. Alvarez-Cuesta Members of the EAACI Immunotherapy Subcommittee Members of the ESPACI Immunotherapy CommitteeSearch for more papers by this authorB. Björkstén, B. Björkstén Members of the ESPACI Immunotherapy CommitteeSearch for more papers by this authorJ. Bousquet, J. Bousquet Members of the EAACI Immunotherapy SubcommitteeSearch for more papers by this authorD. Caillot, D. Caillot Members of the EAACI Immunotherapy Subcommittee Members of the ESPACI Immunotherapy CommitteeSearch for more papers by this authorG. W. Canonica, G. W. Canonica Members of the EAACI Immunotherapy SubcommitteeSearch for more papers by this authorG. Passalacqua, G. Passalacqua Members of the EAACI Immunotherapy SubcommitteeSearch for more papers by this authorP. Saxonis-Papageorgiou, P. Saxonis-Papageorgiou Members of the EAACI Immunotherapy SubcommitteeSearch for more papers by this authorE. Valovirta, E. Valovirta Members of the EAACI Immunotherapy Subcommittee Members of the ESPACI Immunotherapy CommitteeSearch for more papers by this author First published: 29 April 2007 https://doi.org/10.1111/j.1398-9995.1998.tb03793.xCitations: 116 Position paper by the working group on local immunotherapy of the European Academy ot Allergology and Clinical Immunology (EAACI) Immunotherapy Subcommittee and the European Society of Pcdiatric Allergy and Clinical Immunology (ESPACI) Immuno-therapy Committee. AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL References 1 Watkins AD. The role of alternative therapies in the treatment of allergic diseases. Clin Exp Allergy 1994; 24: 813– 25. 2 Holt PG, Batty JE, Turner KJ. Inhibition of specific IgE responses in mice by pre-exposure to inhaled antigen. Immunology 1981; 42: 409– 17. 3 Holt PG, Scdgewick JD. Suppression of IgE responses following inhalation of antigen. A natural homeostatic mechanism which limits sensitization to aeroallergens. Immunol Today 1987; 8: 14– 26. 4 Holt PG, Britten D, Sedgewick JD. Suppression of IgE responses by antigen inhalation: studies on the role of genetic and environmental factors. Immunology 1987; 60: 97– 102. 5 Holt PG, McMenamin C. Defence against allergic sensitization in healthy lung: the role of inhalation tolerance. Clin Exp Allergy 1989; 19: 55– 62. 6 Mowart AM. The regulation of immune response to dietary proteins. Immunol Today 1987; 8: 93– 6. 7 Holt PG, Vines J, Britten D. Sublingual allergen administration. I. Selective suppression of IgE production in rats by high allergen doses. Clin Allergy 1988; 18: 229– 34. 8 Chen Y, Kuchroo VK, Inobe J, Hafler DA, Weiner HL. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 1994; 265: 1237– 40. 9 Eriksson K, Ahlfors E, George-Chandy A, Kaiserlian D, Czerkinsky C. Antigen presentation in the murine oral epithelium. Immunology 1996; 88: 147– 52. 10 Vanwilsem EJ, Vanhoogstraten IM, Breve J, Scheper RJ, Kraal G. Dendritic cells of the oral mucosa and the induction of oral tolerance. A local affair. Immunology 1994; 83: 128– 32. 11 Hasseus B, Dahlgren U, Bergenholtz G, Jontell M. Antigen presenting capacity of Langerhans cells from rat oral epithelium. J Oral Pathol Med 1995; 24: 56– 60. 12 Manetti R, Parronchi P, Giudizi MG, et al. Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J Exp Med 1993; 177: 1199– 1204. 13 Macatinia SE, Hosken NA, Litton M, et al. Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+ T cells. J Immunol 1995; 154: 5071– 9. 14 Bagnasco M, Mariani G, Passalacqua G, et al. Absorption and distribution kinetics of the major Parietaria judaica (Par j 1) allergen administered by noninjectable routes to healthy human beings. J Allergy Clin Immunol 1997; 100: 122– 9. 15 Cohn JR, Pizzi A. Determinants of patient compliance with allergen immunotherapy. J Allergy Clin Immunol 1993; 91: 734– 7. 16 Malling H-J, Weeke B. Immunotherapy. EAACI Position paper. Allergy 1993; 38 Suppl 14: 9– 45. 17 Hejjaoui J, Ferrando R, Dhivert H, Michel FB, Bousquet J. Systemic reactions occurring during immunotherapy with standardized pollen extracts. J Allergy Clin Immunol 1992; 89: 925– 33. 18 Tabar AI, Garcia BE, Rodriguez A, Olaguibel JM, Muro MD, Quirce S. A prospective safety-monitoring study of immunotherapy with biologically standardized extracts. Allergy 1993; 48: 450– 3. 19 Curtis HH. The immunizing cure of hay fever. Med News (NY) 1900; 77: 16– 18. 20 Black JH. The oral administration of pollen. J Lab Clin Med 1927; 12: 1156– 9. 21 Feinberg SM, Foran FL, Lichtenstein MR. Oral pollen therapy in ragweed pollinosis. J Am Med Assoc 1940; 115: 23– 9. 22 Committee on the Safety of Medicine. CSM update. De-sensitizing vaccines. BMJ 1986; 293: 948. 23 Greenberg MA, Kaufman CR, González GE. Late and immediate systemic allergic reactions to inhalant allergen immunotherapy. J Allergy Clin Immunol 1986; 77: 865– 70. 24 Lockey RF, Benedict LM, Turkeltaub PC, Bukantz SC. Fatalities from immunotherapy and skin testing. J Allergy Clin Immunol 1987; 79: 660– 77. 25 Dreborg S, editors.Frew A. Allergen standardization and skin tests. Allergy 1993; 48 Suppl 14: 49– 82. 26 Giovane AL, Bardare M, Passalacqua G, et al. A three-year double-blind placebo-controlled study with specific oral immunotherapy to Dermatophagoides: evidence of safety and efficacy in paediatric patients. Clin Exp Allergy 1994; 24: 53– 9. 27 Malling H-J. New ideas in allergen-specific immunotherapy. Am J Rhinol 1990; 4: 155– 8. 28 Johansson SGO, Deuschl H, Zetterström O. Use of glutar-aldehyde-modified timothy grass pollen extract in nasal hyposensitisation treatment of hay fever. Int Arch Allergy Appl Immunol 1979; 60: 447– 60. 29 Nickelsen JA, Goldstein S, Mueller U, Wypych J, Reisman RE, Arbesman CE. Local intranasal immunotherapy for ragweed allergic rhinitis, I. Clinical response. J Allergy Clin Immunol 1981; 68: 33– 40. 30 Welsh PW, Zimmermann EM, Yunginger JW, Kern EB, Gleich GJ. Preseasonal intranasal immunotherapy with nebulized short ragweed extract. J Allergy Clin Immunol 1981; 67: 237– 42. 31 Schumacher MJ, Pain MC. Intranasal immunotherapy and polymerized grass pollen allergens. Allergy 1982; 37: 241– 8. 32 Georgitis JW, Reisman RE, Clayton WF, Mueller UR, Wypych JI, Arbesman CE. Local intranasal immunotherapy for grass-allergic rhinitis. J Allergy Clin Immunol 1983; 71: 71– 6. 33 Georgitis JW, Clayton WF, Wypych JI, Barde SH, Reisman RE. Further evaluation of local intranasal immunotherapy with aqueous and allergoid grass extracts. J Allergy Clin Immunol 1984; 74: 694– 700. 34 Andri L, Senna GE, Betteli C, et al. Local nasal immunotherapy in allergic rhinitis to Parietaria. A double-blind controlled study. Allergy 1992; 47: 318– 23. 35 Andri L, Senna G, Betteli C, Givanni S, Andri G, Falagiani P. Local nasal immunotherapy for Dermatophagoides-indueed rhinitis: efficacy of a powder extract. J Allergy Clin Immunol 1993; 91: 987– 96. 36 Passalacqua G, Albano M, Ruffoni S, et al. Nasal immunotherapy to Parietaria: evidence of reduction of local inflammation. Am J Respir Crit Care Med 1995; 152: 461– 6. 37 D'Amato G, Lobefalo G, Liccardi G, Cazzola M. A double-blind, placebo-controlled trial of local nasal immunotherapy in allergic rhinitis to Parietaria pollen. Clin Exp Allergy 1995; 25: 141– 8. 38 Andri L, Senna G, Andri G, et al. Local nasal immunotherapy for birch allergic rhinitis with extract in powder form. Clin Exp Allergy 1995; 25: 1092– 9. 39 Andri L, Senna G, Betteli C, et al. Local nasal immunotherapy with extract in powder form is effective and safe in grass-pollen rhinitis. A double blind study. J Allergy Clin Immunol 1996; 97: 34– 41. 40 Cirla AM, Sforza N, Roffi GP, et al. Preseasonal intranasal immunotherapy in birch-alder allergic rhinitis. A double-blind study. Allergy 1996; 51: 299– 305. 41 Bardare M, Zani G, Novembre E, Vierucci A. Local nasal immunotherapy with a powder extract for grass pollen induced rhinitis in pediatric ages: a controlled study. J Investig Allergol Immunol 1996; 6: 359– 63. 42 Metha SB, Morrison Smith J. Nasal hyposensitization and hay fever. Clin Allergy 1975; 5: 279– 84. 43 Georgitis JW, Nickelsen JA, Wypych JI, Kane JH, Reisman RE. Local nasal immunotherapy. Efficacy of low-dose aqueous ragweed extract. J Allergy Clin Immunol 1985; 75: 496– 500. 44 Georgitis JW, Nickelsen JA, Wypych JI, Barde SH, Clayton WF, Reisman RE. Local intranasal immunotherapy with high-dose polymerized ragweed extract. Int Arch Allergy Appl Immunol 1986; 81: 170– 3. 45 Ariano R, Panzani RC, Chiapella M, Augeri G, Falagiani P. Local immunotherapy of seasonal allergic rhinitis in children due to Parietaria pollen. A preliminary report. Pediatr Asthma Allergy Immunol 1993; 7: 227– 37. 46 Welsh PW, Butterfield JH. Yunginger W, Agarwal MK, Gjeich GJ. Allergen controlled study of intranasal immunotherapy for ragweed hay fever. J Allergy Clin Immunol 1983; 71: 454– 60. 47 Gasparini A, Di Franco G, Malavenda A. Preliminary evaluation of the nasal local specific immunotherapy in mite-sensitive respiratory patients. Perspect ENT Immunol 1991; 5: 29– 33. 48 Filiaci F, Zambetti G, Lo Vecchio A. Specific local immunotherapy with macronized dust in the treatment of seasonal allergic rhinopathy caused by Gramineae. Perspect ENT Immunol 1989; 3: 170– 6. 49 Gaglani B, Borish L, Bartelson BL, Buchmeier A, Keller L, Nelson HS. Nasal immunotherapy in weed-induced rhinitis. Ann Allergy Asthma Immunol 1997; 79: 259– 65. 50 Passalacqua G, Albano M, Pronzato C, et al. Long-term follow-up of nasal immunotherapy to Parietaria: clinical and local immunological effects. Clin Exp Allergy 1997; 27: 904– 8. 51 Crimi E, Voltolini S, Troise C, et al. Local immunotherapy with Dermatophagoides extract in asthma. J Allergy Clin Immunol 1991; 87: 721– 8. 52 Tari MG, Mancino M, Monti G. Immunotherapy by inhalation of allergen in powder in house dust allergic asthma: a double-blind study. J Investig Allergol Clin Immunol 1992; 2: 59– 67. 53 Taudorf E, Weeke B. Orally administered grass pollen. Allergy 1983; 38: 561– 4. 54 Björkstén B, Möller C, Broberger U, et al. Clinical and immunological effects of oral immunotherapy with a standardized birch pollen extract. Allergy 1986; 41: 290– 5. 55 Creticos PS, Naclerio RM, Adkinson F, Norman PS. Efficacy, safety and kinetics of oral ragweed immunotherapy in the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 1990; 85: 165. 56 Leng X, Fu YX, Ye ST, Duan SQ. A double-blind trial of oral immunotherapy for Artemisia pollen asthma with evaluation of bronchial response to pollen allergen and serum-specific IgE antibody. Ann Allergy 1990; 64: 27– 31. 57 Cooper PJ, Darbyshire J, Nunn AJ, Warner JO. A controlled trial of oral hyposensitization in pollen asthma and rhinitis in children. Clin Allergy 1984; 14: 541– 50. 58 Taudorf E, Laursen LC, Djurup R, et al. Oral administration of grass pollen to hay fever patients. An efficacy study in oral hyposensitization. Allergy 1985; 40: 321– 35. 59 Möller C, Dreborg S, Lanner Å, Björkstén B. Oral immunotherapy of children with rhinoconjunctivitis due to birch pollen allergy. A double blind study. Allergy 1986; 41: 271– 9. 60 Mosbech H, Dreborg S, Madsen F, et al. High dose grass pollen tablets used for hyposensitization in hay fever patients. A one-year double blind placebo controlled study. Allergy 1987; 42: 451– 5. 61 Taudorf E. Laursen LC. Lanner Å, et al. Oral immunotherapy in birch pollen hay fever. J Allergy Clin Immunol 1987; 80: 153– 61. 62 Oppenheimer J, Areson JG, Nelson HS. Safety and efficacy of oral immunotherapy with standardized cat extract. J Allergy Clin Immunol 1994; 93: 61– 7. 63 Einarsson R, Renck B, Taudorf E. In vitro studies of degradation of birch and timothy pollen allergen preparations by human duodenal juice. Allergy 1988; 43: 469– 72. 64 van Deusen MA, Angelini BL, Cordoro KM, Seiler BA, Wood L, Skoner DP. Efficacy and safety of oral immunotherapy with short ragweed extract. Ann Allergy Asthma Immunol 1997; 78: 573– 80. 65 Litwin A, Flanagan M, Entis G, et al. Oral immunotherapy with short ragweed extract in a novel encapsulated preparation: a double-blind study. J Allergy Clin Immunol 1997; 100: 30– 8. 66 Taudorf E, Laursen L, Lanner A, Björkstén B, Dreborg S, Weeke B. Specific IgE, IgG, and IgA antibody response to oral immunotherapy in birch pollinosis. J Allergy Clin Immunol 1989; 83: 589– 94. 67 Scadding K, Brostoff J. Low dose sublingual therapy in patients with allergic rhinitis due to dust mite. Clin Allergy 1986; 16: 483– 91. 68 Reilly D, Taylor MA, Beattie NGM, et al. Is evidence for homeopathy reproducible Lancet 1994; 344: 1601– 6. 69 van Niekerk CH, De Wet JI. Efficacy of grass-maize pollen oral immunotherapy in patients with seasonal hay fever: a double blind study. Clin Allergy 1987; 17: 507– 13. 70 Feliziani V, Marfisi RM, Parmiani S. Rush immunotherapy with sublingual administration of grass allergen extract. Allergol Immunopathol (Madr) 1993; 21: 173– 8. 71 Nelson HS, Oppenheimer J, Vatsia GA. Bucheimer A. A double blind placebo controlled evaluation of sublingual immunotherapy with standardized cat extract. J Allergy Clin Immunol 1993; 92: 229– 36. 72 Casanovas M, Guerra F, Moreno C, Miguel R, Maranon F, Daza JC. Double blind placebo controlled clinical trial of preseasonal treatment with allergenic extracts of Olea europaea pollen administered sublingually. J Investig Allergol Clin Immunol 1994; 4: 305– 14. 73 D'Ambrosio FP, Ricciardi L, Isola S, Puccinelli P, Musarra A. Rush sublingual immunotherapy in Parietaria allergic patients. Allergol Immunopathol (Madr) 1996; 24: 146– 51. 74 Tari MG, Mancino M, Monti G. Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite. A double blind study. Allergol Immunopathol (Madr) 1990; 18: 277– 84. 75 Sabbah A, Hassoun S, Le Sellin J, André C, Sicard H. A double blind placebo controlled trial by the sublingual route of immunotherapy with a standardized grass pollen extract. Allergy 1994; 49: 309– 13. 76 Feliziani V, Lattuada G, Parmiani S, Dall'Aglio PP. Safety and efficacy of sublingual rush immunotherapy with grass allergen extracts. A double blind study. Allergol Immunopathol (Madr) 1995; 23: 224– 30. 77 Troise C, Voltolini S, Canessa A, Pecora S, Negrini AC. Sublingual immunotherapy in Parietaria pollen induced rhinitis: a double blind study. J Investig Allergol Clin Immunol 1995; 5: 25– 30. 78 Hirsch T, Sahn M, Leupold W. Double-blind placebo-controlled study of sublingual immunotherapy with house dust mite extract (D.pt.) in children. Pediatr Allergy Immunol 1997; 8: 21– 7. 79 Passalacqua G, Albano M, Fregonese L, et al. Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunetivitis. Lancet 1998; 351: 629– 32. 80 Rebien W, Puttonen E, Maasch HJ. Stix E, Wahn U. Clinical and immunological response to oral and subcutaneous immunotherapy with grass pollen extracts. A prospeetive study. Eur J Pediatr 1982; 138: 341– 4. 81 Palacios AS, Medina FS. Rua-Figueroa AL, Millares CB, Santos SR, Marrero JAG. Comparative clinical-immunological study of oral and subcutaneous immunotherapy in children with extrinsic bronchial asthma. Allergol Immunopathol (Madr) 1989; 17: 323– 9. 82 Urbanek R, Bürgelin KH, Kahle W, Wahn U. Oral immunotherapy with grass pollen in enterosoluble capsules. Eur J Pediatr 1990; 149: 545– 50. 83 Moscato G, Rossi G, Dellabianca A, Pisati A, Vinci G, Biale C. Local immunotherapy by inhalation of a powder extract in asthma due to house dust mite Dermatophagoides pteronyssinus: a double-blind comparison with parenteral immunotherapy. J Investig Allergol Clin Immunol 1991; 1: 383– 94. 84 Corbetta L, Pesiri P, Ferro G, Mander A. Improvement of fog and exercise induced asthma after local and subcutaneous immunotherapy in mite asthma. Allergol Immunopathol (Madr) 1992; 20: 60– 6. 85 Piazza I, Bizzaro N. Humoral response to subcutaneous, oral, and nasal immunotherapy for allergic rhinitis due to Dermatophagoides pteronyssinus. Ann Allergy 1993; 71: 461– 9. 86 Bernadis P, Agnoletto M, Puccinelli P, Parmiani S, Pozzan M. Injective versus sublingual immunotherapy in Alternaria tenuis allergic patients, J Investig Allergol Clin Immunol 1996; 6: 55– 62. 87 Quirino T, Lemoli E, Siciliani E, Parmiani S, Milazzo F. Sublingual versus injective immunotherapy in grass pollen allergic patients: a double blind (double dummy) study. Clin Exp Allergy 1996; 26: 1253– 61. 88 Horak F, Wheeler AW. Oral hyposensitisation with enteric-coated allergens as extension therapy following a basic subcutaneous course of injections. Int Arch Appl Immunol 1987; 84: 74– 8. 89 Trede NS, Urbanek R. Combination of parenteral and oral immunotherapy in grass pollen-allergic children. A double-blind controlled study of clinical and immunological efficacy. Allergy 1989; 44: 272– 80. Citing Literature Volume53, Issue10October 1998Pages 933-943 ReferencesRelatedInformation
Referência(s)